As the deadliest primary brain tumor, glioblastoma is a stubborn foe. In addition to being aggressive, glioblastoma hasn’t responded to immunotherapies that have succeeded against some other types of cancers. Now, University of Florida Health and Massachusetts General Hospital researchers have found a combination approach using those therapies that are showing promise.
The results in animal models have advanced the treatment toward early trials in human patients. The findings are published in the Proceedings of the National Academy of Sciences.
The research was led by Jeffrey K. Harrison, Ph.D., a professor in the UF College of Medicine’s department of pharmacology and therapeutics and Rakesh K. Jain, Ph.D., a professor of tumor biology at Massachusetts General Hospital. Other UF Health contributors included Joseph A. Flores-Toro, Ph.D., a recent Biomedical Sciences graduate student in the department of pharmacology and therapeutics; Duane A. Mitchell, M.D. Ph.D., a professor in the Lillian S. Wells Department of Neurosurgery, and co-director of the Preston A. Wells Jr. Center for Brain Tumor Therapy; Matthew Sarkisian, Ph.D., an associate professor in the department of neuroscience.Learn more about New Combination Therapy Slows Deadly Brain Tumor in Mice, UF Health Researchers Find.